TY - JOUR
T1 - Exposure assessment
T2 - Recommendations for nanotechnology-based pesticides
AU - Stone, D.
AU - Harper, B.J.
AU - Harper, S.L.
AU - Lynch, I.
AU - Dawson, K.
N1 - Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Given the development of nanotechnology within numerous scientific disciplines, it is likely that nanoscale products have been and will be used for agricultural, vector, and urban pest control prior to a complete evaluation of exposure and risk. Significant differences may exist between nanotechnology-based pesticides (NBPs) and conventional pesticides, primarily due to size and surface characteristics. These differences may result in changes in bioavailability, sensitivity, dosimetry, and pharmacokinetics. This paper considers the role of exposure assessment in the regulation of NBPs. While the existing regulatory infrastructure for pesticides is well established, several issues specific to NBP exposure are discussed, including: (1) disclosures of nanoparticle characteristics in product formulations; (2) additional uncertainty factors for NBPs with inadequate data; (3) route-specific approaches for assessing exposure; (4) testing with the commercial form of NBPs; (5) initiation of a health surveillance program; and (6) development of educational programs.
AB - Given the development of nanotechnology within numerous scientific disciplines, it is likely that nanoscale products have been and will be used for agricultural, vector, and urban pest control prior to a complete evaluation of exposure and risk. Significant differences may exist between nanotechnology-based pesticides (NBPs) and conventional pesticides, primarily due to size and surface characteristics. These differences may result in changes in bioavailability, sensitivity, dosimetry, and pharmacokinetics. This paper considers the role of exposure assessment in the regulation of NBPs. While the existing regulatory infrastructure for pesticides is well established, several issues specific to NBP exposure are discussed, including: (1) disclosures of nanoparticle characteristics in product formulations; (2) additional uncertainty factors for NBPs with inadequate data; (3) route-specific approaches for assessing exposure; (4) testing with the commercial form of NBPs; (5) initiation of a health surveillance program; and (6) development of educational programs.
UR - http://www.scopus.com/inward/record.url?partnerID=yv4JPVwI&eid=2-s2.0-78049469921&md5=287dd463ba73ae496c48c4c9bdbb2436
M3 - Article
AN - SCOPUS:78049469921
SN - 1232-1087
VL - 16
SP - 467
EP - 474
JO - International Journal of Occupational Medicine and Environmental Health
JF - International Journal of Occupational Medicine and Environmental Health
IS - 4
ER -